About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Phase 1 Trial of BLU-285 Shows Promise in Treating Mastocytosis

by Rishika Gupta on December 11, 2017 at 3:40 PM
Font : A-A+

Phase 1 Trial of BLU-285 Shows Promise in Treating Mastocytosis

An investigational drug called BLU-285 has demonstrated faster response time and fewer side effects in response to an advanced or aggressive form of systemic mastocytosis (AdvSM) disease condition. The BLU-285 drug mainly works by targeting KIT D816V genetic mutation found in almost all the cases of AdvSM. The results of this trial were presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta.

The once-daily pill, BLU-285, targets a mutation called KIT D816V that is found in almost all cases of AdvSM, a disease that originates in mast cells, a type of white blood cell. "We are seeing a high rate of rapid and durable responses, with a very low rate of adverse side effects, in patients with an advanced or aggressive form of the disease," said lead study author Daniel J. DeAngelo, MD, PhD, director of clinical and translational research, adult leukemia, Dana-Farber Cancer Institute. "The rapidity of the improvement is extremely dramatic."

Advertisement


Most standard chemotherapy drugs work by killing cells in the body that are growing and dividing rapidly; this includes cancer cells, but the drugs don't distinguish between cancer cells and normal cells.

Targeted drugs, by contrast, are designed to zero in on and neutralize genetic features of cancer cells that make them different from normal cells and allow the cancer cells to grow and spread. Because they are designed to specifically target cancer cells while leaving normal cells alone, targeted therapies usually have different, and sometimes milder, adverse side effects than standard chemotherapy drugs.
Advertisement

In this study, BLU-285 quickly produced lasting reductions in both cellular levels of mast cells and molecular levels of the mutated gene. Of 18 evaluable patients with aggressive systemic mastocytosis, 72 percent had an overall response, and 100 percent had disease control.

The normal role of mast cells is to help protect the body from infection and aid in wound healing. Systemic mastocytosis occurs when mast cells start to grow uncontrollably. In its aggressive form, it spreads rapidly throughout the body, invading the liver, spleen, and organs of the gastrointestinal tract. It can also develop into a rare blood cancer, mast cell leukemia. Existing treatments for AdvSM are of limited effectiveness.

BLU-285 was designed specifically to block the genetic mutation that drives the growth and spread of mast cells in AdvSM, DeAngelo said. The primary objective of the Phase 1 study was to identify the "maximum tolerated dose" of BLU-285 - that is, the highest dose that could be given without unacceptable levels of adverse effects. Secondary objectives were to assess the drug's activity in the body, including anti-cancer activity.

In the BLU-285 dose escalation study, the first three patients enrolled received a low dose of the study drug and were monitored for adverse effects. If no adverse events were seen, the next three patients received a higher dose, and so on. Dose escalation was stopped when adverse events were seen in 30 percent of the patients treated. Dosing began at 30 mg per day and increased in a stepwise fashion to 400 mg per day.

This Phase 1 trial was designed primarily to identify a safe dose of BLU-285, not to evaluate the drug's effectiveness. The investigators are now planning a Phase 2 study that will assess the effectiveness of a once-daily dose of 300 mg of BLU-285 in a larger number of patients.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Turmeric: Magic Ingredient to Keep you Healthy in Winter
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Mastocytosis 

Recommended Reading
Protein Produced by Mast Cells can Predict Risk of Life Threatening Complications Among Dengue Patients
A joint study reveals that the risk of life threatening complications among people infected with ......
Why Do Some Opioid Drugs Cause Severe Itching?
Opioid drugs used for the treatment of pain can cause severe itching because of a receptor MRGRPX2 ....
First Complete DNA Study of Mast Cell Leukemia Hints at Possibility to Improve Therapy
First comprehensive study of the evolution of the DNA of a patient with mast cell leukemia (MCL), .....
Leukemia
Encyclopedia section of medindia gives general information about Leukemia...
Mastocytosis
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various org...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use